Autor: |
Pluchart C; Department of Paediatric Oncology/Hematology, CHU de Reims, Reims, France. cpluchart@chu-reims.fr.; EA3801-HERVI, Université de Reims Champagne-Ardenne, Reims, France. cpluchart@chu-reims.fr.; American Hospital, CHU de Reims, 47 rue Cognacq Jay, 51095, Reims, France. cpluchart@chu-reims.fr., Barbe C; Department of Clinical Research, CHU de Reims, Reims, France., Poitevin G; EA3801-HERVI, Université de Reims Champagne-Ardenne, Reims, France., Audonnet S; Plateau technique de cytométrie en flux -URCACyt, Pôle Santé, Université de Reims Champagne-Ardenne, Reims, France., Nguyen P; EA3801-HERVI, Université de Reims Champagne-Ardenne, Reims, France.; Department of Hematology Laboratory, CHU de Reims, Reims, France. |
Abstrakt: |
In paediatric acute lymphoblastic leukaemia (ALL), focus has shifted towards preventing treatment-related complications, including venous thromboembolism, the cause of significant mortality and morbidity. To better understand thrombogenic mechanisms during induction treatment, we studied the number, origin and procoagulant activity of extracellular vesicles (EVs) and P-selectin level throughout the induction course in 24 paediatric patients. EVs were mainly of platelet origin. We observed a significant increase in EV number, in platelet EV number and P-selectin level throughout the induction course. There was a correlation between higher EV and platelet EV number, P-selectin level, higher platelet count and leucocyte count. We also observed a correlation between higher EV procoagulant activity and higher platelet count and leucocyte count and higher P-selectin level. Older age and T phenotype were associated with a higher EV procoagulant activity. Platelet EV generation may play a role in thrombogenic complications in ALL patients and could serve as a biomarker to identify patients with a high risk of thrombosis. As a marker of platelet activation, P-selectin may be another relevant marker with the advantage of being easier to analyse in clinical practice. |